Eurycomanone
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Chemical Class | Quassinoid diterpenoid |
| Molecular Formula / CAS | C₂₀H₂₄O₉ · CAS 84633-29-4 |
| Primary Botanical Source(s) | Tongkat Ali / pasak bumi (Eurycoma longifolia) |
| Plant Part | Root |
| Typical Content | The most abundant quassinoid in Eurycoma longifolia root and the marker compound most commercial extracts are standardised to, typically 0.8-1.5% (also known as Pasakbumin A) |
| Solubility / Format | Available as standardised extract powders at multiple potency grades |
| Sourcing Status | Product-live - genuine match via Herbuno’s Tongkat Ali extract line |
| Buy from Herbuno | Eurycomanone 2% Powder (Tongkat Ali Root Extract) |
Name origin: Eurycomanone takes its name from its source genus, Eurycoma, and is also known by the synonym Pasakbumin A, reflecting the Indonesian common name pasak bumi. Traditional use: Tongkat Ali root has been used across Malaysian, Indonesian and broader Southeast Asian traditional medicine for generations as a general tonic and specifically as a male vitality and fertility aid, with folk reputation closely anticipating the modern research focus on testosterone and reproductive parameters. Research trajectory: Early phytochemical work through the 1980s isolated and characterised eurycomanone as the most abundant quassinoid in Eurycoma longifolia root; subsequent research bifurcated into two substantial and largely separate strands - human clinical trials on whole-root extract, standardised to eurycomanone content, for testosterone and male reproductive health, and preclinical cell-based research on isolated eurycomanone specifically for anticancer mechanisms. Commercial source: Tongkat Ali root is the standard commercial source of eurycomanone, and Herbuno’s standardised extract reflects this well-established, genuine botanical match.
Evidence for Eurycomanone Applications
A systematic review and meta-analysis of randomised clinical trials found that Eurycoma longifolia supplementation significantly improved total serum testosterone levels in men, with the effect confirmed in both healthy volunteers and men with clinically diagnosed hypogonadism (standardised mean difference 1.352, 95% CI 0.565 to 2.138); the review noted that most included trials used the same type of commercial extract, standardised to 0.8-1.5% eurycomanone content specifically (Leisegang et al. 2022). This makes eurycomanone one of the more directly clinically relevant marker compounds in the HerbIQ index, given that most human trial evidence is tied to extracts standardised to this exact compound. Claim strength: Moderate.
Beyond total testosterone, related human research on standardised eurycomanone-content extracts has examined semen quality, stress hormone (cortisol) reduction, and self-reported vitality and mood measures, generally in small-to-moderate sized trial populations; the meta-analysis authors specifically identified male hypogonadism as the population most likely to benefit, given the clearer signal observed in that subgroup relative to healthy eugonadal men. Claim strength: Moderate.
Separate from its hormonal research, isolated eurycomanone has demonstrated anticancer activity in multiple cell-line studies. In A549 lung cancer cells, purified eurycomanone inhibited proliferation in a dose-dependent manner and suppressed expression of several tumour-marker proteins including prohibitin and annexin 1 (Tee et al. 2012). More recent mechanistic work in colon cancer cells found eurycomanone inhibits autophagy via mTOR pathway activation, suppressing both proliferation and angiogenesis, proposing eurycomanone as a candidate autophagy-inhibiting anticancer agent (Ye et al. 2022). Claim strength: Emerging.
Eurycomanone has also shown activity against leukaemia (Jurkat and K562) and multiple additional solid tumour cell lines in laboratory testing, alongside separately documented antimalarial activity against Plasmodium falciparum and gastroprotective effects reducing gastric lesion size in rodent ulcer models. This breadth of preclinical activity reflects an actively expanding research area rather than a single validated clinical application beyond the testosterone research discussed above. Claim strength: Emerging.
For formulators, the practical takeaway is that eurycomanone content is the standard, clinically relevant specification for Tongkat Ali sourcing intent: because most of the human testosterone trial evidence used extract standardised specifically to eurycomanone percentage, a Tongkat Ali product without stated eurycomanone content cannot be reliably connected to that clinical trial literature, regardless of overall extract concentration claims. Claim strength: Moderate.
Dosage & Formulator Specification
Human clinical trials on Eurycoma longifolia have most commonly used extract standardised to 0.8-1.5% eurycomanone, generally dosed in the range of 200-400 mg extract per day; Herbuno’s 2% eurycomanone standardisation sits above this typical range, so formulators should adjust finished-product inclusion rates accordingly to match target eurycomanone exposure levels used in the clinical literature.
Analytical quantification of eurycomanone is performed by HPLC, the standard method used across both the clinical trial literature and commercial Tongkat Ali quality control; formulators should request HPLC-verified eurycomanone percentage specifically, since Tongkat Ali root also contains other quassinoids (eurycomanol, eurycomalactone) that are analytically distinct and not interchangeable with eurycomanone content.
Because Tongkat Ali is one of the more heavily adulterated botanical ingredients in commercial supply, given high demand and variable wild-harvest availability, formulators should request documentation confirming genuine Eurycoma longifolia root sourcing alongside eurycomanone-specific analytical verification, rather than relying on eurycomanone percentage alone as proof of authentic material.
Regulatory positioning for eurycomanone follows established Tongkat Ali botanical-ingredient precedent in most markets, given its long traditional medicinal use across Southeast Asia; no eurycomanone-specific regulatory limit exists. Formulators making testosterone-related claims should note the meta-analysis finding that benefit was most clearly demonstrated in men with diagnosed hypogonadism rather than uniformly across all users.
Frequently Asked Questions — Eurycomanone
Eurycomanone is the specific compound most commercial Tongkat Ali extracts are standardised to, and a meta-analysis of clinical trials found that extract standardised to 0.8-1.5% eurycomanone significantly improved total testosterone levels in men, with the clearest benefit in men with diagnosed hypogonadism.
The clearest clinical trial signal was seen in men with diagnosed hypogonadism (clinically low testosterone) rather than uniformly across all users. Healthy men with normal baseline testosterone showed a less consistent response across the pooled trial data.
Yes. Isolated eurycomanone has shown anticancer activity in laboratory studies across several cell lines including lung, colon and leukaemia cells, plus documented antimalarial and gastroprotective effects in preclinical models. These applications remain at an earlier research stage than the testosterone evidence.
Request HPLC-verified eurycomanone percentage alongside documentation confirming genuine Eurycoma longifolia root sourcing. Tongkat Ali is one of the more heavily adulterated botanical ingredients in commercial supply, so eurycomanone content alone should not be treated as sole proof of authenticity without supporting sourcing documentation.
Related compounds: Icariin, L-DOPA